[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:burkitt-lymphoma:cd22-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Burkitt Lymphoma","CD22 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[20],"Phase 1","2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z"]